US FDA To Withdraw Pain Drug Guidance As Part Of Response To Opioid Epidemic

"At least four" guidances will replace it, Commissioner Gottlieb notes in frank update which states "I don’t want to look back ten years from now and wish there were more policies we had pursued, or more steps we had taken, to stop the advance of this crisis."

FDA entrance sign 2016

The US FDA is planning to withdraw its existing guidance on the development of pain products and replace it with more specific documents as part of the agency's efforts to combat the opioid crisis.

FDA has discussed the idea of additional guidance previously, but Commissioner Scott Gottlieb offered the most details to date in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet